Announcement PDF Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Paradigm Biopharmaceuticals Limited ABN 94 169 346 963 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of director Paul Rennie Date of last notice 23 October 2024 Part 1 - Change of director's relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part. Direct or indirect interest (1) Direct (2) Indirect (3) Indirect (4) Direct (5) Indirect Nature of indirect interest (including registered holder) (1) N/A (2) KZEE Pty Ltd ATF KZEE Superannuation Fund (3) EAR Investments Pty Ltd ATF EAR Investments Trust (4) N/A (5) KZEE Pty Ltd ATF KZEE Superannuation Fund Date of change (1) N/A (2) N/A (3) 21 November 2024 (4) N/A (5.1) N/A (5.2) N/A + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director's Interest Notice No. of securities held prior to change (1) 200,000 - FULLY PAID ORDINARY SHARES (2) 10,767,843 - FULLY PAID ORDINARY SHARES (3) 797,355 - FULLY PAID ORDINARY SHARES (4) 8,545,848 - FULLY PAID ORDINARY SHARES (5.1) 613,059 - FULLY PAID ORDINARY SHARES (5.2) 349,500 - LISTED OPTIONS @ $0.65 EXP 30/11/2024 Class (1) FULLY PAID ORDINARY SHARES (2) FULLY PAID ORDINARY SHARES (3) FULLY PAID ORDINARY SHARES (4) FULLY PAID ORDINARY SHARES (5.1) FULLY PAID ORDINARY SHARES (5.2) LISTED OPTIONS @ $0.65 EXP 30/11/2024 Number acquired (1) NIL (2) NIL (3) NIL (4) NIL (5.1) NIL (5.2) NIL Number disposed (1) NIL (2) NIL (3) 197,355 (4) NIL (5.1) NIL (5.2) NIL Value/Consideration (1) N/A (2) N/A (3) N/A (4) N/A (5.1) N/A (5.2) N/A No. of securities held after change (1) 200,000 - FULLY PAID ORDINARY SHARES (2) 10,767,843 - FULLY PAID ORDINARY SHARES (3) 600,000 - FULLY PAID ORDINARY SHARES (4) 8,545,848 - FULLY PAID ORDINARY SHARES (5.1) 613,059 - FULLY PAID ORDINARY SHARES (5.2) 349,500 - LISTED OPTIONS @ $0.65 EXP 30/11/2024 + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 2 Appendix 3Y Change of Director's Interest Notice Nature of change (1) N/A (2) N/A (3) Employee shares buy-back (4) N/A (5.1) N/A (5.2) N/A Part 2 - Change of director's relevant interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change N/A Interest acquired N/A Interest disposed N/A Value/Consideration N/A Interest after change N/A Part 3 - +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3